1.Annual report which provides a comprehensive overview of the Revolution Medicine for 2019; 2.The SHP2 Inhibitor RMC-4630 in Patients withKRAS-mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-man Ph...
2.2 针对EGFR突变NSCLC治疗的联合用药策略EGFR突变是我国最为常见的NSCLC驱动基因变异, 目前酪氨酸激酶抑制剂(tyrosine kinase inhibitor, TKI)耐药是EGFR抑制剂的治疗难点。相较于EGFR突变型, SHP2对EGFR野生型下游ERK磷酸化的促进作用要更加显著[41...
加科思在北京、上海和波士顿设有研发中心,拥有诱导异位药物研发平台(IADDP)和 iADC 平台。 网址:https://en.prnasia.com/releases/global/jacobio-announces-china-cde-clearance-for-phase-iii-clinical-trial-of-shp2-inhibitor-plus-kras-g12c-inhibitor-436901.shtml...
Navire Pharma Inc., a BridgeBio company, has initiated Phase 1 clinical trials to evaluate the safety, tolerability, and preliminary efficacy of BBP-398, a SHP2 inhibitor, in patients with advanced solid tumors. We understand that some patients may wish to access our investigational drug that ha...
2. The SHP2 Inhibitor RMC-4630 in Patients with KRAS-mutant Non-Small Cell Lung Cancer:Preliminary Evaluation of a First-in-man Phase 1 Clinical Trial, revmed.egnyte.com/dl/vk 3. 加科思药业集团有限公司招股说明书:www1.hkexnews.hk/app/se 4. AstraZeneca follows Amgen down KRAS/SHP2 combo...
Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients withKRAS p.G12Cmutated solid tumors.doi:10.1200/JCO.2024.42.16_suppl.3008633113008#Background:Resistance to KRAS G12C inhibitor in non-small cell lung ...
(BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the first patient with non-small cell lung cancer (NSCLC) has been dosed in its Phase 1/2 clinical trial of BBP-398, an investigational SHP2 inhibitor, with Bristol Myers ...
5d). Various clinical trials of SHP2 inhibitor therapies for solid tumors have taken different approaches to using RAS mutation status in their eligibility criteria, from no exclusions (e.g., JAB-3068) to excluding specific mutation types (RASQ61X for BBP-398; RASQ61X and KRASG13X for ...
R. et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur. J. Cancer 50, 2072–2081 (2014). Article PubMed CAS Google Scholar Jänne, P. A...
In September 2019, a small molecule oral anti-tumor drug JAB-3312, which was independently developed by Jacobio with global intellectual property rights, obtained clinical permission in China, and the clinical trials will soon be conducted concurrently i